WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administrations Peripheral and…
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a…
Biogen Inc. BIIB received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
FDA advisors voted against Biogens investigational ALS drug, which could become the first to target a genetic cause of the…
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session....…
An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to…
The FDA staff on Monday said Biogens investigational ALS drug tofersen may have a "clinical benefit" on a rare and…
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Biogen stock has dropped about 40% from its record high....…
Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
read more...…
Most of Biogens (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi…
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice…
Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session....…
In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day....…
Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von RBC Capital Markets:
Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bewertet die Aktie von Biogen…
The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy....…
It could be a make or break year for the biotech....…
CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of…
The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for…
The FDA grants priority review to Biogen (BIIB) and Eisais sBLA seeking traditional approval of Alzheimers disease drug, Leqembi. The…
Pharmabranche - Die amerikanische Roche-Tochter Genentech hat einem Bericht zufolge am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…
Die Roche-Tochter Genentech hat laut einem Bericht der Nachrichtenagentur Reuters am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…
...By Blake Brittain
(Reuters) - Roches Genentech Inc sued Biogen......…
WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Tuesday said the Biologics License Application (BLA) for lecanemab, has…
New York (www.aktiencheck.de) - Rating-Update:
Das Anlagevotum der Analysten von Morgan Stanley für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…
U.S. neurologists increasingly favor Novartis MS portfolio, particularly Kesimpta EXTON, Pa., Feb. 17, 2023 /PRNewswire/ -- According to Biogens earnings…
Toronto (www.aktiencheck.de) - Rating-Update:
Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bewertet die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…
New York (www.aktiencheck.de) - Rating-Update:
Philip Nadeau, Analyst von Cowen and Company, stuft die Biogen-Aktie (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP,…
INNOCARE-B (09969.HK) opened lower by 14.9% this morning (16th), and has once nosedived 30.1% to bottom at $8.51, a fresh…
BIIB earnings call for the period ending December 31, 2022....…
Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter…
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do…
Die US-Inflationsdaten sorgten gestern für eine kleine Berg- und Talfahrt bei den US-Indizes. Am Ende ging der Dow Jones mit…
Starke Einzelhandelsumsätze im Januar verunsichern am Mittwoch die Anleger an der Wall Street und drücken die Indizes ins Minus. 30…
Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments...…
WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) reported Wednesday that profit for the fourth quarter surged 50 percent from…
Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower…
WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced earnings for its fourth quarter that increased from the same period last year…
Shares of Biogen Inc. BIIB gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings…